A recent study in Nature Materials introduces an inhalable nanozyme treatment for viral pneumonia, showing promising results in reducing inflammation and viral load in various mouse models. The nanozyme, CeTA-K1tkP, demonstrates broad-spectrum effects and biocompatibility, offering a potential new approach to treating pneumonia and other inflammatory conditions.
Lilly agrees to acquire biopharmaceutical firm Versanis for $1.9bn
Lilly intends to bolster outcomes in patients with cardiometabolic conditions through the Versanis takeover. Credit: Jonathan Weiss / Shutterstock.com. Eli Lilly and Company has signed an
July 17, 2023